DECIDE.
PARTICIPATE.
EXPLORE.
MAKE A
DIFFERENCE.

You can be one of the FIRST to contribute to research that
may lead to improved outcomes of sickle cell disease.

 
 
First-Background.jpg

Be among the FIRST to participate

FIRST (Ferriprox Iron Overload Sickle Cell Trial) is a 52-week study comparing two iron chelating drugs, deferiprone vs. deferoxamine, in patients with sickle cell disease or other anemias.


Additional information about the FIRST study is available at  ClinicalTrials.gov
Identifier: NCT02041299

 
iStock-157646333.jpg

Be among the FIRST to make a difference

Some patients with sickle cell disease or other anemias have too much iron in their bodies as a result of receiving regular blood transfusions. The FIRST study is looking at the safety and effectiveness of the iron-chelating drug deferiprone in these patients.

The FIRST study is open to males and females 2 years of age and over.